Company Description
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.
The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
| Country | United States |
| Founded | 2022 |
| IPO Date | Jan 20, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Quang Pham |
Contact Details
Address: 822 A1A North, Suite 306 Ponte Vedra, Florida 32082 United States | |
| Phone | 904 300 0701 |
| Website | cadrenal.com |
Stock Details
| Ticker Symbol | CVKD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001937993 |
| ISIN Number | US1276362076 |
| Employer ID | 88-0860746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Quang X. Pham | Chairman and Chief Executive Officer |
| Matthew K. Szot CPA, CPA | Co-Founder and Chief Financial Officer |
| Jeffrey Cole | Chief Operating Officer |
| Dr. James J. Ferguson FACC, M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 6, 2025 | 144 | Filing |
| Oct 2, 2025 | 144 | Filing |
| Oct 1, 2025 | 144 | Filing |
| Oct 1, 2025 | 144 | Filing |
| Sep 29, 2025 | 144 | Filing |
| Sep 29, 2025 | 144 | Filing |
| Sep 29, 2025 | 144/A | Filing |
| Sep 25, 2025 | 144 | Filing |
| Sep 25, 2025 | 144 | Filing |
| Sep 24, 2025 | 144 | Filing |